Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

Compare

339.11

+1.05 (0.31%)

At close: Feb 2, 2026, 4:00 PM EST

336.06

-3.05 (-0.90%)

Pre-market: Feb 3, 2026, 8:00 AM EST

Alnylam Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	1,490	966.43	812.69	866.39	819.98	496.58
Short-Term Investments	1,234	1,728	1,627	1,326	1,616	1,378
Cash & Short-Term Investments	2,725	2,695	2,439	2,192	2,436	1,874
Cash Growth	-2.00%	10.46%	11.27%	-9.98%	29.94%	22.02%
Accounts Receivable	964.77	405.31	327.79	237.96	198.57	102.41
Other Receivables	-	-	-	-	-	500
Receivables	964.77	405.31	327.79	237.96	198.57	602.41
Inventory	75.38	78.51	89.15	128.96	86.36	75.2
Prepaid Expenses	188.04	116.96	126.38	132.92	88.08	62.77
Total Current Assets	3,953	3,295	2,983	2,692	2,809	2,615
Property, Plant & Equipment	693.14	693.93	725.79	738.63	733.63	706.51
Long-Term Deferred Tax Assets	98.56	116.86	10.1	-	-	-
Other Long-Term Assets	107.15	133.9	111.29	115.48	101.1	85.77
Total Assets	4,852	4,240	3,830	3,546	3,643	3,407
Accounts Payable	117.59	88.42	55.52	98.09	73.43	51.97
Accrued Expenses	1,154	795.16	654.73	513.78	372.33	299.27
Current Portion of Long-Term Debt	115.69	113.02	54.99	40.29	37.08	13.32
Current Portion of Leases	44.76	41.89	41.51	41.97	40.55	36.87
Current Unearned Revenue	2.54	55.48	102.75	42.11	149.48	127.21
Other Current Liabilities	121.25	92.31	58.28	31.68	22.84	56.64
Total Current Liabilities	1,555	1,186	967.79	767.92	695.71	585.27
Long-Term Debt	2,389	2,359	2,343	2,269	1,827	1,250
Long-Term Leases	223.42	229.54	243.1	261.34	281.35	293.04
Long-Term Unearned Revenue	-	-	188.18	193.79	152.36	225.09
Pension & Post-Retirement Benefits	-	-	-	-	-	5.2
Other Long-Term Liabilities	449.43	398.11	308.44	212.58	98.96	32.71
Total Liabilities	4,618	4,173	4,051	3,705	3,055	2,391
Common Stock	1.32	1.29	1.26	1.24	1.2	1.16
Additional Paid-In Capital	7,415	7,388	6,811	6,455	6,058	5,644
Retained Earnings	-7,160	-7,288	-7,010	-6,569	-5,438	-4,585
Comprehensive Income & Other	-21.78	-34.52	-23.38	-44.65	-33.26	-43.62
Shareholders' Equity	233.89	67.09	-220.64	-158.22	588.2	1,016
Total Liabilities & Equity	4,852	4,240	3,830	3,546	3,643	3,407
Total Debt	2,773	2,743	2,683	2,613	2,186	1,593
Net Cash (Debt)	-48.69	-48.92	-243.24	-420.15	249.87	281.67
Net Cash Growth	-	-	-	-	-11.29%	-77.14%
Net Cash Per Share	-0.37	-0.38	-1.95	-3.45	2.11	2.45
Filing Date Shares Outstanding	132.11	129.46	125.95	124.13	120.21	117
Total Common Shares Outstanding	131.79	129.29	125.79	123.93	120.18	116.43
Working Capital	2,397	2,109	2,015	1,924	2,113	2,030
Book Value Per Share	1.77	0.52	-1.75	-1.28	4.89	8.73
Tangible Book Value	233.89	67.09	-220.64	-158.22	588.2	1,016
Tangible Book Value Per Share	1.77	0.52	-1.75	-1.28	4.89	8.73
Land	-	9.08	9.08	9.08	9.08	9.08
Buildings	-	294.51	271.65	269.32	262.64	262.64
Machinery	-	225.2	202.89	173.1	137.86	120.15
Construction In Progress	-	7.67	30.1	14.6	80.75	28.01
Leasehold Improvements	-	236.69	235.41	230.85	152.05	149.51

Updated Oct 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q